Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you manage your health, your finances and your family life as Canada reopens.
Visit the hub

A team of blood transfusion experts from across Canada is planning the world’s largest clinical trial of a potential treatment for COVID-19.

The study, which will involve 1,000 patients from across the country, will include at least 40 Canadian hospitals, and is being overseen by doctors from the University of Montreal, University of Ottawa, University of Toronto, McMaster and the University of British Columbia, among other schools.

The experimental treatment involves injecting antibody-rich plasma from patients who have recovered from the virus into those who are still infected. This approach has only been tried in small trials in China, Singapore, South Korea and the U.S. It is part of a global race to find a treatment for the disease, with researchers also focusing on antivirals and medications used to treat malaria.

Story continues below advertisement

The latest on the coronavirus: Toronto to open more food banks in libraries; Ontario reports 309 new cases

How to safely shop for groceries during COVID-19 pandemic

Donation centres across Canada will extract plasma, a straw-yellow liquid component of blood, from recovered patients and test that it has a certain minimum number of antibodies to be considered useful as an immunotherapy. Known as convalescent plasma, the material will then be frozen, sent to participating hospitals and infused into a critical patient to see if it can help treat their illness. In the early stages of infection, the body doesn’t produce the antibodies needed to fight off the novel coronavirus, according to Dr. Donald Arnold, a hematologist at McMaster University who is leading the trial.

“The theory is that people who have recovered from COVID infection may have antibodies to fight the virus,” Dr. Arnold said.

Canada’s two blood suppliers, Canadian Blood Services and Héma-Québec, will be managing donations from those who have fully recovered from COVID-19.

Late last month, a small Chinese study of five ventilated patients suggested the technique could be used to temper the severity of coronavirus. Three of the five patients were able to be weaned off ventilators days after receiving plasma. During the SARS outbreak, 80 patients were treated with convalescent plasma. A review of that study showed that the earlier the transfusion, the better the outcome of the patient. None of the patients in that trial experienced adverse reactions to the treatment.

In late March, U.S. regulators allowed doctors to begin collecting recovered patients’ plasma for emergency use. Dr. Arnold, the lead of the Canadian trial, admits that the treatment is a “Hail Mary.” While transfusion therapies aren’t typically risky for the patient, there is a chance this trial won’t have a significant impact in treating COVID-19, instead draining resources and time.

Dr. Michael Joyner of the Mayo Clinic, which will run the American national supply chain of plasma, said on Wednesday that their findings will be shared with other countries in virtual real time.

The plan for the Canadian trial came together in just days. A group of a dozen hematologists and scientists joined a Zoom call on March 29 and worked out a plan – a process that usually takes between six months and a year for a typical trial, according to Dr. Arnold.

Story continues below advertisement

The researchers soon learned that a parallel trial was being developed in Quebec. The following day, they merged into one large unit, with different participating institutions tackling potential subdivisions of research. Dr. Arnold said that by April 1, nearly every hospital in the country treating COVID-19 patients had signed on to participate.

Dr. Dana Devine, Canadian Blood Services’ head scientist, said that while China is now collecting donations from multiple sites, there hasn’t yet been a large patient study with a control group – meaning that certain patients don’t receive plasma – which is the gold standard for clinical trials and would be key in determining the widespread efficacy of this treatment.

She said that the group is now finalizing funding and infrastructure while Canada’s two blood banks work with provincial health ministries to contact all recovered positive COVID-19 cases about donating.

Donating plasma is no different than conventional blood donation, according to Dr. Devine, and takes about 45 minutes. She said each donor’s plasma will be studied for its virus-fighting viability.

All patients who are hospitalized and need oxygen will be able to sign up for the trial.

“It’s a flip of a coin – two-thirds of patients will get the antibody-rich blood, with the other third being a control group,” Dr. Arnold said. The control group would receive standard care.

Story continues below advertisement

The trial could be completed in as little as three months. Dr. Arnold said they are realistically looking at six to 10 months before they have definitive results.

“The challenge is to get to an answer as quickly as possible so that we can start using this product if it’s truly effective, or realize it’s not and stop using it,” Dr. Arnold said.

Dr. Rulan Parekh of SickKids Hospital in Toronto said there will also be a pediatric component to the trial, and that there will be multiple concurrent studies, including those to determine longer-term immunotherapies.

“I’ll be doing a larger study, with Dr. Devine, of donors to understand their immunity,” she said. “We also hope to get viable candidates to help create a large repository, so scientists can use their blood to think about immunotherapies.” Those could include a treatment that could help protect front-line medical workers who have significantly greater chance of infection.

Richard Carl, who recovered from COVID-19 after contracting it while on a ski trip in Colorado in February, said he will be a donor.

Mr. Carl did not require hospitalization, but was treated at Sunnybrook Hospital in Toronto. He was cleared of the virus on March 25, and as this study came together last week, he was nominated to its advisory board as the patient representative.

Story continues below advertisement

“There is a real feeling of helplessness in the world today,” Mr. Carl said from his home in Toronto. “The thought of asking someone to help fix this thing – I couldn’t say yes fast enough.”

Mr. Carl said he hopes others who have recovered from the virus will come out in larger numbers to donate plasma.

“We’re going to need blood, and those who have been infected, like me, need to join us in this,” he said. “We need to help fight this, and also help these front-line health-care workers – they are putting themselves in harm’s way to save lives.”

Using convalescent plasma to battle a virus isn’t a new discovery, Dr. Arnold said, adding doctors first discovered this therapy at the end of the 1918-19 Spanish flu pandemic.

“There’s nothing 21st century about this – this is so old school,” he said.

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters.

In the interests of public health and safety, our coronavirus news articles are free for anyone to access. However, The Globe depends on subscription revenue to support our journalism. If you are able, please subscribe to globeandmail.com. If you are already a subscriber, thank you for your support.

Your subscription helps The Globe and Mail provide readers with critical news at a critical time. Thank you for your continued support. We also hope you will share important coronavirus news articles with your friends and family. In the interest of public health and safety, all our coronavirus news articles are free for anyone to access.

Follow related topics

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies